Safety and Superiority of Penicillamine in Radiosensitization of Recurrent Head and Neck Cancer

Summary

Our preclinical study confirmed that copper accumulation can lead to radioresistance in vitro and in vivo, and reducing the concentration of copper with copper chelator help to overcome radioresistance. Therefore, the investigators plan to carry out a prospective interventional phase II clinical trial to explore the safety and efficacy of penicillamine (a common copper chelator) as a radiosensitizer in the treatment of recurrent head and neck cancer.

Timeline

Start

2023-11-15

Primary completion

2024-10-30

Completion

2025-06-01

Drugs

Indications